Orphan Drug “Improvements” May Be Undercut By New Market Share Fees
Executive Summary
The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.
You may also be interested in...
Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees
Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.
Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees
Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.
Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says
The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.